Human γδ T Cell Subsets and Their Clinical Applications for Cancer Immunotherapy

被引:27
作者
Lee, Derek [1 ,2 ]
Rosenthal, Carl J. [3 ]
Penn, Natalie E. [1 ]
Dunn, Zachary Spencer [1 ,4 ]
Zhou, Yang [1 ,2 ]
Yang, Lili [1 ,2 ,5 ,6 ]
机构
[1] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Mol Biol Inst, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA
[4] Univ Southern Calif, Mork Family Dept Chem Engn & Mat Sci, Los Angeles, CA 90089 USA
[5] Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA 90095 USA
[6] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA
关键词
gamma delta T (gamma delta T) cells; cancer immunotherapy; chimeric antigen receptor T (CAR-T) cells; allogeneic cell therapy; butyrophilins (BTN); zoledronate (ZOL); DENDRITIC CELLS; ZOLEDRONIC ACID; ADOPTIVE IMMUNOTHERAPY; EFFICIENTLY ENHANCE; ADAPTIVE IMMUNITY; TUMOR-CELLS; IN-VITRO; PHASE-I; RECEPTOR; EXPANSION;
D O I
10.3390/cancers14123005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gamma delta (gamma delta) T cells are a minor population of T cells that share adaptive and innate immune properties. In contrast to MHC-restricted alpha beta (alpha beta) T cells, gamma delta T cells are activated in an MHC-independent manner, making them ideal candidates for developing allogeneic, off-the-shelf cell-based immunotherapies. As the field of cancer immunotherapy progresses rapidly, different subsets of gamma delta T cells have been explored. In addition, gamma delta T cells can be engineered using different gene editing technologies that augment their tumor recognition abilities and antitumor functions. In this review, we outline the unique features of different subsets of human gamma delta T cells and their antitumor properties. We also summarize the past and the ongoing pre-clinical studies and clinical trials utilizing gamma delta T cell-based cancer immunotherapy.
引用
收藏
页数:22
相关论文
共 150 条
[1]   Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma [J].
Abe, Yu ;
Muto, Masato ;
Nieda, Mie ;
Nakagawa, Yasunori ;
Nicol, Andrew ;
Kaneko, Touru ;
Goto, Shigenori ;
Yokokawa, Kiyoshi ;
Suzuki, Kenshi .
EXPERIMENTAL HEMATOLOGY, 2009, 37 (08) :956-968
[2]   Human CD1-restricted T cell recognition of lipids from pollens [J].
Agea, E ;
Russano, A ;
Bistoni, O ;
Mannucci, R ;
Nicoletti, I ;
Corazzi, L ;
Postle, AD ;
De Libero, G ;
Porcelli, SA ;
Spinozzi, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (02) :295-308
[3]   Allogenic V9V2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma [J].
Alnaggar, Mohammed ;
Xu, Yan ;
Li, Jingxia ;
He, Junyi ;
Chen, Jibing ;
Li, Man ;
Wu, Qingling ;
Lin, Li ;
Liang, Yingqing ;
Wang, Xiaohua ;
Li, Jiawei ;
Hu, Yi ;
Chen, Yan ;
Xu, Kecheng ;
Wu, Yangzhe ;
Yin, Zhinan .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[4]   LAG3 (CD223) as a cancer immunotherapy target [J].
Andrews, Lawrence P. ;
Marciscano, Ariel E. ;
Drake, Charles G. ;
Vignali, Dario A. A. .
IMMUNOLOGICAL REVIEWS, 2017, 276 (01) :80-96
[5]   Electroporation of NKG2D RNA CAR Improves Vγ9Vδ2 T Cell Responses against Human Solid Tumor Xenografts [J].
Ang, Wei Xia ;
Ng, Yu Yang ;
Xiao, Lin ;
Chen, Can ;
Li, Zhendong ;
Chi, Zhixia ;
Tay, Johan Chin-Kang ;
Tan, Wee Kiat ;
Zeng, Jieming ;
Toh, Han Chong ;
Wang, Shu .
MOLECULAR THERAPY-ONCOLYTICS, 2020, 17 :421-430
[6]   The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vδ1 TCR [J].
Bai, Li ;
Picard, Damien ;
Anderson, Brian ;
Chaudhary, Vinod ;
Luoma, Adrienne ;
Jabri, Bana ;
Adams, Erin J. ;
Savage, Paul B. ;
Bendelac, Albert .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2012, 42 (09) :2505-2510
[7]   Homing and memory patterns of human γδ T cells in physiopathological situations [J].
Battistini, L ;
Caccamo, N ;
Borsellino, G ;
Meraviglia, S ;
Angelini, DF ;
Dieli, F ;
Cencioni, MT ;
Salerno, A .
MICROBES AND INFECTION, 2005, 7 (03) :510-517
[8]   Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA [J].
Bauer, Stefan ;
Groh, Veronika ;
Wu, Jun ;
Steinle, Alexander ;
Phillips, Joseph H. ;
Lanier, Lewis L. ;
Spies, Thomas .
JOURNAL OF IMMUNOLOGY, 2018, 200 (07) :2231-2233
[9]   Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma [J].
Bennouna, Jaafar ;
Bompas, Emmanuelle ;
Neidhardt, Eve Marie ;
Rolland, Frederic ;
Philip, Irene ;
Galea, Celine ;
Salot, Samuel ;
Saiagh, Soraya ;
Audrain, Marie ;
Rimbert, Marie ;
Micheaux, Sylvie Lafaye-de ;
Tiollier, Jerome ;
Negrier, Sylvie .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (11) :1599-1609
[10]   Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vγ9Vδ2 T lymphocyte agonist in patients with solid tumors [J].
Bennouna, Jaafar ;
Levy, Vincent ;
Sicard, Helene ;
Senellart, Helene ;
Audrain, Marie ;
Hiret, Sandrine ;
Rolland, Frederic ;
Bruzzoni-Giovanelli, Heriberto ;
Rimbert, Marie ;
Galea, Celine ;
Tiollier, Jerome ;
Calvo, Fabien .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (10) :1521-1530